Antiretroviral Therapy and Communities of Color

摘要: The current HIV treatment guidelines from both the DHHS and IAS indicate that best choices for first-line therapy include either efavirenz (EFV) or a ritonavir-boosted protease inhibitor combined with fixed dose combination nucleoside backbone (Table 1).1,2 These recommendations have evolved long list of clinical trials, which shown these regimens to be very effective in suppressing replication allowing immune preservation/restoration short term. There is little published literature suggest choice treatment-naive patients should determined by patient’s race ethnic background. Several studies examined effect on outcome mixed results. Some demonstrated blacks (and some cases Hispanics) lower response rates than whites while others suggested comparable outcomes given access. This chapter will discuss initial HIV-infected individuals, review disparities therapies, possible contributing factors drive disparities.